All Articles

Editorial Commentary 
BRAF V600E mutant, PD-L1 TPS 90% NSCLC: 1st line treatment with targeted therapy
Edwin H. Yau
Precision Cancer Medicine  
2021;
4:
10  
Editorial Commentary 
The role of Anti-PD-1/PD-L1 monotherapy as first-line treatment of metastatic NSCLC without targetable mutations and PD-L1 TPS 1–49%
Arpeet T. Shah, Joel W. Neal
Precision Cancer Medicine  
2021;
4:
9  
Editorial Commentary 
Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes
Naiyarat Prasongsook, Thanyanan Reungwetwattana
Precision Cancer Medicine  
2021;
4:
8  
Editorial Commentary 
Concerns and controversies regarding ipilimumab-based immunotherapy in the first-line treatment of non-small cell lung cancer
Ivy Riano, Narjust Duma
Precision Cancer Medicine  
2021;
4:
7  
Editorial Commentary 
ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)
Patrick C. Ma
Precision Cancer Medicine  
2021;
4:
6  
Case Report 
Precision oncology in EGFR positive non-small cell lung cancer: breaking the 10-year barrier—a case report
Camila Ordóñez-Reyes, Alejandro Ruiz-Patiño, Oscar Arrieta, Lucia Zatarain-Barrón, Leonardo Rojas, Gonzalo Recondo, Luisa Ricaurte, Andrés F. Cardona, on behalf of Latin American Consortium for the Investigation of Lung Cancer (CLICaP)
Precision Cancer Medicine  
2021;
4:
5  
Case Report 
Unusual pattern of recurrence and atypical visceral metastases in extremity soft tissue sarcoma: a case report
Paula Sedano, Carmen González-San Segundo, Marta Rodríguez-Pertierra, Francisco Díaz-Gutiérrez, Adriana Medrano, Carolina Agra-Pujol
Precision Cancer Medicine  
2021;
4:
4  
Review Article 
A narrative review of immune checkpoint inhibitors in early stage triple negative breast cancer
Ana-Alicia Beltran-Bless, Terry L. Ng
Precision Cancer Medicine  
2021;
4:
3  
Editorial Commentary 
Checkpoint inhibitors first in patients with metastatic non-small cell lung cancer harboring BRAFV600E mutation with PD-L1 90%—a debate in a niche population
Yusra F. Shao, Ammar Sukari, Misako Nagasaka
Precision Cancer Medicine  
2020;
3:
35  
Editorial Commentary 
CM227/CM9-LA: evidence supporting ipilimumab-based immunotherapy in the first-line treatment of metastatic NSCLC
Emily F. Collier, Sarah B. Goldberg
Precision Cancer Medicine  
2020;
3:
34  
Editorial Commentary 
ADAURA: a definitive answer to the wrong question
Howard West
Precision Cancer Medicine  
2020;
3:
32  
Letter to the Editor 
Utility of high-throughput sequencing of T-cell receptor rearrangements in assessing treatment response in patients with mature T-cell lymphoma
Pooja M. Phull, Carlyn R. Tan, Henry C. Fung, Paul A. Fields, Yang Liu, Jasmine Zain, Nathan H. Fowler, R. Katherine Alpaugh, Yasuhiro Oki, Stefan K. Barta
Precision Cancer Medicine  
2020;
3:
31  
Case Report 
Use of 3D-planning and tantalum in revision total hip arthroplasty after failed iliac bone allograft for Ewing sarcoma: a case report
Michele Fiore, Andrea Sambri, Riccardo Zucchini, Claudio Giannini, Fulvia Taddei, Massimiliano De Paolis
Precision Cancer Medicine  
2020;
3:
30  
Case Report 
Effective tyrosine kinase inhibitor re-treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer patient: a case report
Alessandro Galletti, Marco Russano, Fabrizio Citarella, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini
Precision Cancer Medicine  
2020;
3:
29  
Case Report 
Feasibility of ultra-central stereotactic ablative irradiation in lung cancer undergoing nivolumab: a case report
Valerio Nardone, Maria Grazia Calvanese, Maria Mormile, Francesca Maria Giugliano, Pierpaolo Correale, Alfonso Reginelli, Salvatore Cappabianca, Cesare Guida
Precision Cancer Medicine  
2020;
3:
28  
Case Report 
Micrometastatic breast cancer presenting as abnormal uterine bleeding: case report
Noah Gomez, Mark McNeely, Jaya Ruth Asirvatham, Ashwin S. Akki
Precision Cancer Medicine  
2020;
3:
27  
Review Article 
A narrative review of BRAF alterations in human tumors: diagnostic and predictive implications
Lynette M. Sholl
Precision Cancer Medicine  
2020;
3:
26  
Original Article 
Central nervous system progression and liquid biopsy in patients with oncogene addicted non-small cell lung cancer treated with ALK/ROS1 inhibitors
Mihaela Aldea, Damien Vasseur, Cristina Teixidó, Laura Mezquita
Precision Cancer Medicine  
2020;
3:
25  
Editorial 
On opposing ideas
Grace K. Dy
Precision Cancer Medicine  
2020;
3:
24  
Case Report 
“Lazarus effect” in patient affected by lung adenocarcinoma carrying EGFR, CTNNB1, MET exon 11 and PIK3CA mutations treated with gefitinib
Nicole Conci, Filippo G. Dall’Olio, Vittoria Comellini, Stefano Brocchi, Rita Golfieri, Andrea Ardizzoni
Precision Cancer Medicine  
2020;
3:
23  
Case Report: Precision Oncology Tumor Board 
Prolonged immune checkpoint inhibitor response of a patient with a RET rearranged non-small cell lung cancer and high tumour mutational burden: case report and review of the literature
Safiye Dursun, Tom E. J. Theunissen, Xiaofei Li, Ernst-Jan M. Speel, Lizza E. L. Hendriks
Precision Cancer Medicine  
2020;
3:
22  
Case Report: Precision Oncology Tumor Board 
Trastuzumab-Pertuzumab resistance in a case of HER2-del16 expressing colorectal cancer—a case report
Sayak Ghatak, Kevin Lin, Emil Lou, Andrew C. Nelson
Precision Cancer Medicine  
2020;
3:
21  
Review Article 
A narrative review of salvage therapy in small cell lung cancer
Saira Farid, Stephen V. Liu
Precision Cancer Medicine  
2020;
3:
20  
Review Article 
Prognostic impact of targetable genetic variants in resected adenocarcinoma of the lung: a narrative review and model proposal for precise evaluation
Masaoki Ito, Yoshihiro Miyata, Morihito Okada
Precision Cancer Medicine  
2020;
3:
19  
Editorial Commentary 
Current and future perspectives in lung cancer prevention
Adrián González-Marrón, Juan Carlos Martín-Sánchez, Jose M. Martínez-Sánchez
Precision Cancer Medicine  
2020;
3:
18  
Case Report: Precision Oncology Tumor Board 
Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J. Piper-Vallillo, Hollis Viray, Adeel M. Khan, Deepa Rangachari, Daniel B. Costa
Precision Cancer Medicine  
2020;
3:
17  
Case Report 
Hepatic lymphoepithelioma-like carcinoma: a case report with literature review
Chunxiu Yang, Yueying Li, Yanyan Chen, Shu-Yuan Xiao
Precision Cancer Medicine  
2020;
3:
16  
Review Article 
Nutrition, disease and underlying molecular mechanisms
Aamer M. Qazi, Rabia Tabassum, Fatima Arshad, Aysha Shaukat, Warda Qazi, Muhammad Tahir Javaid, Abdul Manan
Precision Cancer Medicine  
2020;
3:
15  
Review Article 
NTRK and NRG1 gene fusions in advanced non-small cell lung cancer (NSCLC)
Alessandro Russo, Ana Rita Lopes, Katherine Scilla, Ranee Mehra, Vincenzo Adamo, Julio Oliveira, Stephen V. Liu, Christian Rolfo
Precision Cancer Medicine  
2020;
3:
14  
Original Article 
Factors associated with the extent of resection of glioblastoma
Thara Tunthanathip, Suphavadee Madteng
Precision Cancer Medicine  
2020;
3:
12  
Editorial Commentary 
Cancer immunotherapy: lessons from the parasites to improve fighting against tumors
Alexandre Morrot
Precision Cancer Medicine  
2020;
3:
11  
Case Report: Precision Oncology Tumor Board 
Exploiting homologous recombination repair alterations in metastatic castrate-resistant prostate cancer: a case report and literature review
Stephen Zachary Peeke, Robert Lopez, Benjamin Gartrell
Precision Cancer Medicine  
2020;
3:
10  
Case Report: Precision Oncology Tumor Board 
Utilizing genomic profiling in a patient with a thoracic malignancy of uncertain primary: case report
Jose N. Galeas, Nishi Shah, Shabnam Ridvi, Jennifer Chuy
Precision Cancer Medicine  
2020;
3:
9  
Case Report: Precision Oncology Tumor Board 
Targeting EGFR mutations needs to be more precise with co-mutations
Paul R. Walker, Nitika Sharma, Praveen Namireddy
Precision Cancer Medicine  
2020;
3:
8  
Review Article 
Non-small cell lung cancer PDL1 >50%—should we go single or combo?
Waleed Kian, Laila C. Roisman, Dina Levitas, Nadav Wallach, Adam Abo-Sharb, Aharon Y. Cohen, Alexander Yakobson, Nir Peled, Yulia Dudnik
Precision Cancer Medicine  
2020;
3:
7  
Review Article 
Annotating the next generation sequencing report
Miguel A. Molina-Vila, Clara Mayo-de-las-Casas, Mónica Garzón-Ibáñez, Núria Jordana-Ariza, Beatriz García-Peláez, Ariadna Balada-Bel, Rafael Rosell
Precision Cancer Medicine  
2020;
3:
6  
Review Article 
Non-small cell lung cancer targetable mutations: present and future
Peter Vu, Sandip Pravin Patel
Precision Cancer Medicine  
2020;
3:
5  
Review Article 
Circulating tumor cells: moving forward into clinical applications
Zahra Eslami-S, Luis Enrique Cortés-Hernández, Catherine Alix-Panabières
Precision Cancer Medicine  
2020;
3:
4  
Original Article 
Significance of alectinib in anaplastic lymphoma kinase-tyrosine kinase inhibitors for anaplastic lymphoma kinase-positive patients with non–small cell lung cancer
Yasuhiro Chikaishi, Kenichi Kobayashi, Hiroki Matsumiya, Akihiro Taira, Yusuke Nabe, Shinji Shinohara, Taiji Kuwata, Masaru Takenaka, Soichi Oka, Ayako Hirai, Kouji Kuroda, Naoko Imanishi, Yoshinobu Ichiki, Fumihiro Tanaka
Precision Cancer Medicine  
2020;
3:
3  
Editorial 
Sharing data: a requirement for expanding precision oncology
Olivier Trédan
Precision Cancer Medicine  
2020;
3:
2  
Editorial 
The current and future revolution in lung cancer screening and management
Waleed Kian, Nadav Wallach, Nir Peled
Precision Cancer Medicine  
2020;
3:
1  
Editorial 
How to add value to research?
Peter Kapitein
Precision Cancer Medicine  
2019;
2:
39  
Editorial Commentary 
Immunotherapy approaches to beat tumors
Alexandre Morrot
Precision Cancer Medicine  
2019;
2:
38  
Editorial 
Precision surgery, it matters
Marcelo Jimenez
Precision Cancer Medicine  
2019;
2:
37  
Review Article 
How to recognize and manage hyper-progression and pseudo-progression during immune checkpoint blockade in non-small cell lung cancer
Francesco Facchinetti, Giuseppe Lo Russo, Marcello Tiseo, Marina Chiara Garassino, Roberto Ferrara
Precision Cancer Medicine  
2019;
2:
35